



R. A. KUVADIA & CO.
CHARTERED ACCOUNTANTS

11-12, Bibi Mansion, 1st Floor, Near Yoga Institute,
Prabhat Colony, Santacruz (East), Mumbai-400 055.
Mobile : +91 8369191242 / 8369514810
E-mail : rashmikantca@yahoo.co.in
cakuvadia@gmail.com

In Reply Please Quote

INDEPENDENT AUDITOR'S REPORT

TO
THE MEMBERS OF
EVERY PHARMACEUTICALS PRIVATE LIMITED

Report on the Audit of the Financial statements

Opinion

We have audited the accompanying financial statements of **EVERY PHARMACEUTICALS PRIVATE LIMITED** ("the Company"), which comprise the Balance Sheet as at 31st March 2023, the Statement of Profit and Loss (including other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ('Ind AS') and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2023, the loss and total comprehensive loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted the audit of financial statements in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted Company.

Information Other than the financial statements and Auditor's Report Thereon

The Company's Board of Directors are responsible for the preparation of other information. The other information comprises the information included in the Director's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of our audit, or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management and Board of Directors for the Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Indian Accounting Standards (IndAS) and other accounting principles generally accepted in India.



This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Audit (SAs) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, specified under section 143 (10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one



resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act 2013, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system, in relation to the financial statements in place and the operating effectiveness of such controls;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management;
- Conclude on the appropriateness of Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation;
- Obtain sufficient appropriate audit evidence regarding the financial statement of the Company to express an opinion on the financial statements.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced.

We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the **Annexure "A"**, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by section 197(16) of the Act based on our audit, we report that the Company has not paid any remuneration to its directors during the year. Therefore, the provisions of and limits laid down under section 197 read with Schedule V to the Act are not applicable to the Company. The Ministry of Corporate Affairs has not prescribed other details under section 197(16) which are required to be commented upon by us.
3. As required by Section 143(3) of the Act, based on our audit we report that:
 - (a) We have sought and obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit of the accompanying financial statement;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, the Statement of Profit and Loss(including Other Comprehensive Income), Statement of change in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act read with the Rule 7 of the Companies (Account) Rules, 2014.



(e) On the basis of the written representations received from the directors as on 31st March, 2023 taken on record by the Board of Directors, none of the director is disqualified from being appointed as a director in terms of Section 164(2) of the Act ;

(f) With respect to the adequacy of the internal financial controls over financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on adequacy and operating effectiveness of Company's internal financial controls over financial reporting.

4. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations as at 31st March, 2023 which would impact its financial position as at 31st March, 2023.

ii. The Company did not have any long-term contracts including derivative contracts; as such the question of commenting on any material foreseeable losses thereon does not arise.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Funds of the Company for the year ended 31st March, 2023.

iv. a) The Management has represented that, to the best of its knowledge and belief no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

b) The Management has represented that, to the best of its knowledge and belief no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly,



lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Parties or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

c) Based on the audit procedures performed that we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) of Rule 11(e) mentioned above contain any material miss-statement.

v. The Company has not declared or paid dividend for the year ended 31st March, 2023

vi. Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 for maintaining books of account using accounting software which has a feature of recording audit trail (edit log) facility is applicable to the Company with effect from 1st April, 2023, and accordingly, reporting under Rule 11(g) of Companies (Audit and Auditors) Rules, 2014 is not applicable for the financial year ended 31st March, 2023.

Place: Mumbai
Date: 27.05.2023

For R. A. Kuvadia & Co.
Chartered Accountants

F.R.N./195487W



R. A. Kuvadia
(Proprietor)

M. No. 040087

UDIN:23040087BGTMP6391

"Annexure A" to the Independent Auditors' Report of even date on the financial statements of AVERY PHARMACEUTICALS PRIVATE LIMITED

Referred to in paragraph 1 under the heading 'Report on Other Legal & Regulatory Requirement' of our report of even date to the financial statements of the Company for the year ended March 31, 2023:

1) a) A. The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant & equipment.

B. The Company has maintained proper records showing full particulars of intangible assets.

b) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has a phased programme designed to cover all items over a period of 3 years, which in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

c) According to the information and explanations given to us and the records examined by us, we report that the title deeds of immovable properties as disclosed in the financial statements are held in the name of the Company.

d) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not revalued its property, plant and equipment (including right of use assets) during the year.

e) According to the information and explanations given to us and based on our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder. Accordingly, the provisions stated in paragraph 3(i)(e) of the order is not applicable to the Company.

2) a) The inventory has been physically verified during the year at reasonable intervals by the Management. In our opinion, the frequency of the verification, coverage and procedure of such verification is reasonable and appropriate. The



discrepancies noticed on verification between the physical stocks and the book records were not material and have been dealt with in books of account.

b) The Company does not have a working capital limit in excess of Rs 5 Crores sanctioned by banks based on security of current assets. Accordingly, clause 3(ii)(b) of the order is not applicable.

3) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not granted loans to Companies, firms, limited liability partnerships or any other parties covered in the register maintained under Section 189 of the Companies Act, 2013 during the year.

4) In our opinion and according to information and explanation given to us and based on audit procedures performed, the Company has complied with the provisions of section 186 of the Companies Act, 2013. The Company has not granted any loans, made investments or provided guarantees or securities to parties covered under section 185 and 186 of the Companies Act, 2013.

5) The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.

6) In our opinion and according to the information and explanations given to us, the Central Government has not prescribed maintenance of Cost records per the provisions of Section 148 of The Companies Act, 2013.

7) a) According to information and explanations given to us and based on our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Goods and service tax, Income-Tax, Duty of Customs, Value Added Tax, Cess, Provident Fund, Employees State Insurance and other material statutory dues with the appropriate authorities.

b) According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2023 for a period of more than six months from the date on when they become payable.



8) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

9)a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowings or in payment of interest thereon to any lender.

b) Based on the information and explanation given to us, the Company has not been declared a willful defaulter by any bank or financial institution or government or government authority.

c) In our opinion and according to the information and explanations given to us, no money was raised by way of term loans during the year. Accordingly, clause 3(xiv)(c) of the order is not applicable.


d) In our opinion and according to information and explanation given to us and on an overall examination of the financial statements of the Company, no funds were raised by the Company on Short Term basis which have, prima facie, been utilised for long term purposes. Accordingly, clause 3(xiv)(d) of the order is not applicable.

e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its associates. The Company does not have any subsidiaries or joint ventures.

f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its associate.

10) a) Based upon the audit procedures performed and the information and explanations given by the Management, the Company has not raised moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, the provisions of clause 3 (x)(a) of the Order are not applicable to the Company and hence not commented upon.

b) According to the information and explanations given to us and on the basis



of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares (fully, partially or optionally) or convertible debentures during the year. Accordingly, reporting under clause 3(x)(b) of the Order is not applicable to the Company.

11) a) Based upon the audit procedures performed and the information and explanations given by the Management, considering the principles of materiality outlined in the Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government. In view of the above reporting under clause 3 (xi) (b) of the order is not applicable.

c) To the best of our knowledge and according to the information and explanations given to us including the representation made to us by the Management of the Company, there are no whistle-blower complaints received by the Company during the year.

12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 3 (xii) of the Order are not applicable to the Company.

13) In our opinion and according to the information and explanations given to us, all transactions entered into by the Company with the related parties are in compliance with sections 177 and 188 of the Act, where applicable. Further, the details of such related party transactions have been disclosed in the financial statements, as required under Indian Accounting Standard (Ind AS) 24, Related Party Disclosures specified in Companies (Indian Accounting Standards) Rules 2015 as prescribed under section 133 of the Act.

14) In our opinion and based on our examination, the company does not have an internal audit system and is not required to have an internal audit system as per provisions of the Companies Act 2013.

15) Based upon the audit procedures performed and the information and explanations given by the Management, the Company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of Section 192 of the Act are not applicable to the Company.



16) a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clauses 3(xvi)(a) to 3(xvi) (d) of the Order are not applicable.

b) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

c) The Company is not a part of any group (as per the provisions of the Core Investments Companies (Reserve Bank) Directions, 2016 as amended). Accordingly, the requirements of the clause 3(xvi)(d) are not applicable.

17) The Company has incurred cash losses of Rs 55,946.94 (in '000) in the current financial year and Rs 19,820.50 (in '000) in the immediately preceding financial year.

18) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

19) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we give neither any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

20) In our opinion and according to the information and explanations given to us, provisions of Section 135 of the Act are not applicable to the Company. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the order are not applicable.



Place: Mumbai
Date: 27.05.2023

For R. A. Kuvadia & Co.
Chartered Accountants

F.R.N./105487W



R. A. Kuvadia
(Proprietor)

M. No. 040087

UDIN:23040087BGTMXP6391

"Annexure -B" to the Independent Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to financial statements of **EVERY PHARMACEUTICALS PRIVATE LIMITED** ("the Company") as of 31st March 2023 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over the financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over the financial statements reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their



operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls with reference to Financial Statements

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of Management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting


Because of the inherent limitations of internal financial controls over financial statements with reference to these financial statements including the possibility of collusion or improper Management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these Ind AS financial statements to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place: Mumbai
Date: 27.05.2023

For R. A. Kuvadia & Co.
Chartered Accountants
F.R.N. 105487W

R. A. Kuvadia
(Proprietor)
M. No. 040087
UDIN: 23040087BGTMXP6391

Avery Pharmaceuticals Private Limited

Balance sheet as at 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	Notes	As at 31st March, 2023	As at 31st March, 2022
Assets			
Non-current assets			
Property, plant and equipment	3	1,54,932	719
Right of use assets	3A	6,300	7,529
Capital work in progress	3	-	1,60,664
Intangible assets under development	3	4,746	4,917
Financial assets			
(i) Other Financial assets	4	1,697	1,514
Deferred tax assets (net)	25	32,404	11,649
Other non-current assets	5	49	43
		2,00,127	1,87,035
Current assets			
Inventories	6	3,385	4,662
Financial assets			
(i) Trade receivables	7	56	-
(ii) Cash and Cash Equivalents	8	1,625	863
(iii) Other Financial assets	9	40	47
Other current assets	10	22,759	19,539
		27,865	25,111
TOTAL ASSETS		2,27,993	2,12,146
Equity and liabilities			
Equity			
(i) Equity Share capital	11	2,500	2,500
(ii) Other Equity	12	(96,650)	(41,804)
Equity attributable to owners of the company		(94,150)	(39,304)
Non-current liabilities			
Financial liabilities			
(i) Borrowing	13	3,04,978	2,35,462
(ii) Lease Liabilities	3A	8,108	9,301
		3,13,087	2,44,763
Current liabilities			
Financial liabilities			
(i) Trade payables	14		
Total Outstanding dues of micro enterprises and small enterprises		-	-
Total Outstanding dues to Others		2,019	2,205
(ii) Other Financial liabilities	15	2,497	1,545
(iii) Lease liabilities	3A	1,193	965
Provisions	16	829	676
Other current Liabilities	17	2,518	1,296
		9,056	6,687
TOTAL EQUITY AND LIABILITIES		2,27,993	2,12,146
Significant accounting policies	2		

The accompanying notes are an integral part of these financial statements (1-36)

As Per our report of even date.

For R. A. Kuvadia & Co.
Chartered Accountants
M. No. 040087
Rashmikant A. Kuvadia
Proprietor
Membership No. 040087
Place : Mumbai
Date : 27th May 2023



For and on behalf of the Board of Directors
Avery Pharmaceuticals Private Limited

Shilpan Patel
Director
DIN No. 00341068

Neil Patel
Director
DIN No. 00607101

UDIN: 23040087B6TMXP6391

Avery Pharmaceuticals Private Limited

Statement of profit and loss for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	Notes	For the year Ended 31st March, 2023	For the year Ended 31st March, 2022
Income			
Revenue from operations	18	3,482	-
Other income	19	111	71
Total Income		3,593	71
Expenses			
Cost of Raw Materials consumed	20	770	-
Employee Benefit Expenses	21	20,193	5,629
Finance Cost	22	21,989	5,105
Depreciation and amortization expense	3 & 3A	20,625	1,762
Other Expenses	23	15,617	8,393
Total expenses		79,194	20,889
Profit Before Tax		(75,601)	(20,818)
Income tax expenses			
Current Tax		-	-
Deferred tax expense	24	(20,755)	(4,654)
Total Tax Expenses		(20,755)	(4,654)
Profit after tax		(54,846)	(16,164)
Other Comprehensive Income (OCI)			
Items that will not be reclassified to profit or loss			
Remeasurement of Defined Benefit Plan		-	-
Income Tax on remeasurement of Defined Benefit Plan		-	-
Other Comprehensive Income (OCI)		-	-
Total comprehensive income for the year, net of tax		(54,846)	(16,164)
Earnings per equity share			
Basic and Diluted [Nominal value of the shares ₹. 10]	30	(219.38)	(64.66)

The accompanying notes are an integral part of these financial statements (1-36)

As Per our report of even date.

For R.A. Kwadia & Co.
Chartered Accountants



Rashmikant A. Kwadia
Proprietor
Membership No. 040087
Place : Mumbai
Date : 27th May 2023



For and on behalf of the Board of Directors
Avery Pharmaceuticals Private Limited

Shilpan Patel
Director
DIN No. 00341068

Neil Patel
Director
DIN No. 00607101

UDIN: 23040087B6TMXP6391

Avery Pharmaceuticals Private Limited

Cash flow statement for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	Year Ended 31st March, 2023	Year Ended 31st March, 2022
A Cash Flow from Operating Activities		
Net Profit/(Loss) before Tax & Prior Period Items	(75,601)	(20,818)
Adjustment for		
Depreciation	20,625	1,762
Interest Income	(111)	(71)
Finance Cost	21,989	5,105
Unrealised Foreign Exchange gain	(30)	-
Operating Profit before Working Capital Changes	(33,128)	(14,023)
Adjustment for:		
Decrease/ (Increase) in current assets	(3,220)	(2,075)
Decrease/ (Increase) in current Financial asset	7	18
Decrease/ (Increase) in non current Assets	(7)	525
Decrease/ (Increase) in non current Financial asset	(183)	(83)
Increase/(Decrease) in Inventories	1,277	(760)
(Increase)/Decrease in Provisions	153	187
Increase/(Decrease) in Trade Payables	(186)	(486)
Increase/(Decrease) in Trade Receivable	(26)	-
Increase/ (Decrease) in other Financial & Lease Liabilities	(12)	(1,003)
Increase/ (Decrease) in other Liabilities	1,222	108
Cash Generated from operations	(34,103)	(17,592)
Taxes Paid (Including TDS) (net)	-	-
Net Cash used in Operation	(34,103)	(17,592)
B Cash Flow from Investing Activities		
Purchase of Tangible and Intangible Assets	(12,773)	(29,593)
Interest Income	111	71
Net Cash used in Investing Activities	(12,662)	(29,523)
C Cash Flow from Financing Activities		
Loan from Holding Company	69,516	52,074
Finance cost Paid	(21,989)	(5,105)
Net Cash from Financing Activities	47,527	46,969
Net Increase in Cash & Cash Equivalents (A+B+C)	762	(144)
Opening Balance of Cash & Cash Equivalents	863	1,007
Closing Balance of Cash & Cash Equivalent	1,625	863

Notes:

Above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard 7 (Ind AS -7) "Statement of Cash Flow"

The accompanying notes are an integral part of these financial statements (1-36)

As Per our report of even date.

FOR R. A. Kuvadia & Co.
Chartered Accountants
M. No. 040087
Rashmikant A. Kuvadia
Proprietor
Membership No. 040087
Place : Mumbai
Date : 27th May 2023



For and on behalf of the Board of Directors
Avery Pharmaceuticals Private Limited

Shilpan Patel
Director
DIN No. 00341068

Neil Patel
Director
DIN No. 00607101

UDIN: 23040087BGTMXP6391

Avery Pharmaceuticals Private Limited

Statement of Changes in Equity for the year ended Mar 31, 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

a. Equity shares of INR 10/- each issued, subscribed and fully paid

	As at 31st Mar, 2023		As at 31st March, 2022	
	Number of shares	Amount	Number of shares	Amount
Balance at the beginning	2,50,000	2,500	2,50,000	2,500
Changes in equity share capital during the year	-	-	-	-
Balance at the end	2,50,000	2,500	2,50,000	2,500

b. Other Equity

	Reserves and Surplus		
	General Reserve	Retained Earnings	Total
Balance at March 31, 2021		(25,640)	(25,640)
Profit / (Loss) for the year	-	(16,164)	(16,164)
Other comprehensive income (net of tax)	-	-	-
Total comprehensive income for the year	-	(16,164)	(16,164)
Balance at March 31, 2022	-	(41,804)	(41,804)
Profit / (Loss) for the year	-	(54,846)	(54,846)
Other comprehensive income (net of tax)	-	-	-
Total comprehensive income for the year	-	(54,846)	(54,846)
Balance at March 31, 2023	-	(96,650)	(96,650)

The accompanying notes are an integral part of these financial statements (1-36)

As Per our report of even date.

For R.A. Kuvadia & Co.
Chartered Accountants



Rashmikant A. Kuvadia
Proprietor

Membership No. 040087

Place: Mumbai

Date : 27th May 2023

UDIN: 23040087BGTMXP6391



For and on behalf of the Board of Directors
Avery Pharmaceuticals Private Limited

Shilpan Patel

Director

DIN No. 00341068

Neil Patel

Director

DIN No. 00607101

Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023
(All amounts in Indian Rupees in thousand unless otherwise stated)

Note 3 Tangible and Intangible Assets

Particulars	Gross Block			Accumulated Depreciation/Amortisation			Net Block		
	As At 1st April 2022	Additions during the year	Deductions / Retirement during the year	As At 31st March 2023	As At 1st April 2022	Charge for the Year	Deduction / Adjustment during the year	As At 31st March 2023	As At 31st March 2022
A Property, Plant & Equipment									
Factory Building	-	26,726	-	26,726	-	1,578	-	1,578	25,148
Plant & Machinery	-	1,29,587	22	1,29,566	-	14,463	-	14,463	1,15,103
Furniture & Fixtures	-	5,617	-	5,617	-	904	-	904	4,713
Electrical Installation	-	10,729	-	10,729	-	1,722	-	1,722	9,007
Office Equipment	861	454	-	1,315	494	324	-	818	497
Computer	1,005	516	-	1,522	654	404	-	1,058	463
Total (A)	1,867	1,73,629	22	1,75,475	1,148	19,395	-	20,543	1,54,932
B Right of use assets									
Lease Assets	12,303	-	-	12,303	4,774	1,230	-	6,003	6,300
Total (B)	12,303	-	-	12,303	4,774	1,230	-	6,003	7,529
C Capital Work In Progress									
Lease Assets	1,60,664	13,306	1,73,970	-	-	-	-	-	1,60,664
Total (C)	1,60,664	13,306	1,73,970	-	-	-	-	-	1,60,664
D Intangible Assets under Development									
Product Development	4,917	54	225	4,746	-	-	-	-	4,746
Total (D)	4,917	54	225	4,746	-	-	-	-	4,917
Total (A + B + C + D)	1,79,751	1,86,989	1,74,216	1,92,524	5,922	20,625	-	26,546	1,65,977

Particulars	Gross Block			Accumulated Depreciation/Amortisation			Net Block		
	As At 1st April 2021	Additions during the year	Deductions / Retirement during the year	As At 31st March, 2022	As At 1st April 2021	Charge for the Year	Deduction / Adjustment during the year	As At 31st March, 2022	As At 31st March 2021
A Property, Plant & Equipment									
Office Equipment	733	129	-	861	250	245	-	494	367
Computer	819	186	-	1,005	366	288	-	654	352
Total (A)	1,552	315	-	1,867	616	532	-	1,148	937
B Right of use assets									
Lease Assets	12,303	-	-	12,303	3,544	1,230	-	4,774	7,529
Total (B)	12,303	-	-	12,303	3,544	1,230	-	4,774	8,759
C Capital Work In Progress									
Lease Assets	1,31,679	28,985	-	1,60,664	-	-	-	-	1,31,679
Total (C)	1,31,679	28,985	-	1,60,664	-	-	-	-	1,31,679
D Intangible Assets under Development									
Product Development	4,624	293	-	4,917	-	-	-	-	4,624
Total (D)	4,624	293	-	4,917	-	-	-	-	4,624
Total (A + B + C + D)	1,50,158	29,593	-	1,79,751	4,160	1,762	-	5,922	1,45,999



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Capital WIP Ageing Schedule

As at March 31, 2023	Less than			More than		Total
	1 Year	1-2 Years	2-3 Years	3 Years		
Tangible Assets						
Project in Progress	-	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-	-
Intangible Assets						
Project in Progress	-	122	71	4,554	4,746	
Projects temporarily suspended	-	-	-	-	-	-
	-	122	71	4,554	4,746	

As at March 31, 2022	Less than			More than		Total
	1 Year	1-2 Years	2-3 Years	3 Years		
Tangible Assets						
Project in Progress	28,985	32,404	89,339	9,935	1,60,664	
Projects temporarily suspended	-	-	-	-	-	-
	28,985	32,404	89,339	9,935	1,60,664	
Intangible Assets						
Project in Progress	292	71	390	4,164	4,917	
Projects temporarily suspended	292	71	390	4,164	4,917	



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

3A Right to use

(i) Amounts to be recognised in balance sheet as on March 31, 2023

The balance sheet shows the following amounts relating to leases :

Right to use assets	March 31, 2023	March 31, 2022
Lease hold land	6,300	7,529
Total	6,300	7,529

Lease liabilities	March 31, 2023	March 31, 2022
Current	1,193	965
Non - Current	8,108	9,301
Total	9,301	10,266

(ii) Amounts to be recognised in Statement of Profit and Loss for the year ended March 31, 2023

The Statement of Profit and Loss shows the following amounts relating to leases:

Depreciation	March 31, 2023	March 31, 2022
Lease hold land/building	1,230	1,230
Total	1,230	1,230

Interest expenses on lease liabilities (included in finance cost) Rs. 1138 thousand

(iii) Total cash outflow for leases during financial year was :

Particulars	March 31, 2023	March 31, 2022
Operating cash flows : Interest expenses	1,138	1,237
Total	1,138	1,237



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	As at 31st March, 2023	As at 31st March 2022
Note 4		
Other Financial assets		
Security Deposit(Unsecured, considered good)	1,697	1,514
	1,697	1,514
Note 5		
Other non-current assets		
Capital Advances (Unsecured, considered good)	42	21
Prepaid Expenses (Unsecured, considered good)	8	22
	49	43
Note 6		
Inventories		
Stock in trade:		
Raw materials and components	2,577	2,233
Stores and spares	808	2,429
	3,385	4,662
Note 7		
Trade receivables		
<u>Unsecured, considered good</u>		
Outstanding for a period more than six months from the date they are due for payment	-	-
Outstanding for a period less than six months from the date they are due for payment	56	-
	56	-
Note 8		
Cash and Cash Equivalents		
Balance with banks		
On Current Accounts	1,577	812
Cash on Hand	47	51
	1,625	863
Note 9		
Other Financial assets		
Security Deposit(Unsecured, considered good)	40	47
	40	47
Note 10		
Other current assets		
Prepaid Expense (Unsecured, considered good)	385	177
Balance with Government Authorities	21,914	18,908
Advances to Suppliers	277	269
Advances to Employees	183	185
	22,759	19,539



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Note 11

a) Equity share capital : Equity shares of ₹. 10 each

Particulars	As at 31st Mar, 2023		As at 31st March, 2022	
	No. of shares	Amount	No. of shares	Amount
Share Capital				
Authorised share capital Equity shares of ₹. 10 each	5,00,000	5,000	5,00,000	5,000
Issued, Subscribed and Paid Up : Equity shares of ₹. 10 each fully paid	2,50,000	2,500	2,50,000	2,500
	2,50,000	2,500	2,50,000	2,500

b) Reconciliation of number of shares outstanding at the beginning and at the end of the reporting period

	As at 31st Mar, 2023		As at 31st March, 2022	
	No. of shares	Amount	No. of shares	Amount
Outstanding at the beginning of the year	2,50,000	2,500	2,50,000	2,500
Add: Issue of Equity Share Capital	-	-	-	-
Less:	-	-	-	-
Outstanding at the end of the year	2,50,000	2,500	2,50,000	2,500

c) Terms /Rights attached to Equity shares

The company has only one class of equity shares having par value of ₹. 10/- per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

d) Details of shares held by each shareholder holding more than 5% equity shares & Promoters Shareholding

Name of Share holder	As at 31st Mar, 2023		As at 31st March, 2022	
	No. of Shares	% of Holding	No. of Shares	% of Holding
Arrow Greentech Limited	2,47,500	99.00%	2,47,500	99.00%
Total	2,47,500	99.00%	2,47,500	99.00%



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	As at				
	31st March, 2023	31st March 2022			
Note 12					
Other Equity					
Retained earnings					
Opening Balance at the beginning of the year	(41,804)	(25,640)			
Profit / (Loss) for the year	(54,846)	(16,164)			
	(96,650)	(41,804)			
Note 13					
Borrowings					
Loan from Holding Company (refer note no. 29)	3,04,978	2,35,462			
	3,04,978	2,35,462			
Note 14					
Trade Payables					
Total Outstanding dues of micro enterprises and small enterprises (refer note no. 27)	-	-			
Total Outstanding dues to Others	2,019	2,205			
	2,019	2,205			
Trade Payable Ageing					
As at March 31, 2023			Less than 1 Year	1-2 Years	2-3 Years
			More than 3 Years	Total	
(i) MSME	-	-	-	-	-
(ii) Other	1,904	65	50	-	2,019
(iii) Disputed Dues - MSME	-	-	-	-	-
(iv) Disputed Dues - Others	-	-	-	-	-
Total	1,904	65	50	-	2,019
As at March 31, 2022			Less than 1 Year	1-2 Years	2-3 Years
			More than 3 Years	Total	
(i) MSME	-	-	-	-	-
(ii) Other	2,179	26	-	-	2,205
(iii) Disputed Dues - MSME	-	-	-	-	-
(iv) Disputed Dues - Others	-	-	-	-	-
Total	2,179	26	-	-	2,205
Note 15					
Other Financial Liabilities					
Salary and Re - imbursement Payable	2,042	925			
Creditors For Fixed Assets	455	619			
	2,497	1,545			
Note 16					
Provisions					
Provision for expenses	829	676			
	829	676			
Note 17					
Other Current Liabilities					
Statutory liabilities	1,014	796			
Advance from others	1,504	500			
	2,518	1,296			



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Particulars	For the year Ended 31st March, 2023	For the year Ended 31st March, 2022
Note 18		
Revenue from Operations		
Finished Goods	3,475	-
Traded Goods	-	-
Other operating Income		
Scrap Sales	7	-
	3,482	-
Details of Sales Products		
Finished Goods Sold		
Mouth Dissolving Strips (MDS)	3,475	-
	3,475	-
Geography wise revenue from operation		
Export	3,430	-
Local	45	-
	3,475	-
Note 19		
Other income		
Miscellaneous Income	111	71
	111	71
Note 20		
Material Cost & Inventory Adjustments		
Cost of Raw Materials consumed		
Opening stock	2,233	-
Add: Purchases	1,114	-
Less: Closing Stock	2,577	-
	770	-
Note 21		
Employee benefits expenses		
Staff Salaries & Bonus	18,700	5,133
Contribution to Provident & Other Funds	718	100
Gratuity and Leave Encashment	200	100
Staff welfare expenses	575	296
	20,193	5,629
Note 22		
Finance Cost		
Finance Charges	20,851	3,868
Interest on Lease	1,138	1,237
	21,989	5,105



Avery Pharmaceuticals Private Limited**Notes to the financial statements for the year ended 31st March 2023**

(All amounts in Indian Rupees in thousand unless otherwise stated)

Note 23		
Other Expenses		
Electricity, Fuel & Water Charges	2,541	604
Repair & Maintenance - Other	1,580	1,218
Factory Expenses	1,717	-
Freight Expenses	190	7
Insurance Charges	464	294
Legal & Professional Charges	1,624	1,663
Payment to Auditors (exclusive of GST) (refer note No. 31)	95	83
Security charges	858	644
Lease Rent	807	373
Foreign Exchange Loss (Net)	(30)	-
Research and Development Expenses	3,312	1,826
Travelling & Conveyance Expenses	1,486	1,110
Miscellaneous Expenses	973	572
	15,617	8,393
Note 24		
Tax Expenses		
Deferred tax expense	(20,755)	(4,654)
	(20,755)	(4,654)



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

Note 25 Deferred Tax Assets (net)

(i) Movement in deferred tax assets for the year ended March 31, 2023

	Net balance March 31,2022	through Retained earning	Recognised through Profit and Loss	through OCI	Net balance March 31,2023
Property, plant and equipment	(809)	-	(1,458)	-	(2,267)
Other	50	-	(23)	-	27
Rent Equalization	441	-	95	-	536
Brought Forward Losses	12,174	-	22,141	-	34,314
Opening Balance impact of IND AS 116	(207)	-	-	-	(207)
	11,649	-	20,755	-	32,404

(ii) Movement in deferred tax assets for the year ended March 31, 2022

	Net balance March 31,2021	through Retained earning	Recognised through Profit and Loss	through OCI	Net balance March 31,2022
Property, plant and equipment	(525)	-	(284)	-	(809)
Other	76	-	(26)	-	50
Rent Equalization	253	-	187	-	441
Brought Forward Losses	7,397	-	4,777	-	12,174
Opening Balance impact of IND AS 116	(207)	-	-	-	(207)
	6,995	-	4,654	-	11,649



Avery Pharmaceuticals Private Limited**Notes to the financial statements for the year ended 31st March 2023**

(All amounts in Indian Rupees in thousand unless otherwise stated)

- 26 Balances of Sundry Debtors, Sundry Creditors, Deposits, Loans and Advances are subjected to reconciliation and confirmation, necessary adjustment if required, will be made after reconciliation. The management does not expect any material difference affecting the current year's financial statements.
- 27 The Company does not possess information as to which of its suppliers are covered under micro, small and medium Enterprise Development Act, 2006. However, the company is regular in making payment to its suppliers and has not received any claim in respect of interest for delayed payment.
- 28 Based on the guiding principles given in Ind AS 108 - "Operating segments", the Company is primarily engaged in the business of manufacturing of pharmaceutical and nutraceutical products. As the Company's business activity falls within a single primary business segment, the disclosure requirements of Ind AS-108 in this regard are not applicable.
- 29 **Related party disclosures**
Related parties with whom transactions have taken place during the year:

Sr.	Name of Related Party	Relationship
1	Arrow Greentech Limited	Holding Company
2	Shilpan Patel	Key Managerial Personnel
3	Neil Patel	

Transaction with Related Parties & Outstanding Balance as on 31st March, 2023:

Sr. No.	Party Name	Transactions for the year ended	Balances receivable/ (payable) as of	Transactions for the year ended	Balances receivable/ (payable) as of
		March 31, 2023	March 31, 2023	March 31, 2022	March 31, 2022
1	Loan Taken from Arrow Greentech Limited	46,750	(2,41,500)	34,450	(1,94,750)
2	Interest (Net of TDS)	22,766	(63,478)	17,624	(40,712)
3	Service Fees	400	-	400	-

30 Earnings Per Share :

Calculation of basic and diluted EPS is as follows:

Particulars	March 31, 2023	March 31, 2022
Profit for the year attributable to Owners of the Company	(54,846)	(16,164)
Weighted average number of equity shares	2,50,000	2,50,000
Earning per Share Basic / Diluted (Rs.) (On Nominal Value of Rs. 10/- per Share)	(219.38)	(64.66)



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

31 Payment to Auditors (exclusive of GST)

Particulars	March 31, 2023	March 31, 2022
Audit Fees	50	38
Limited Review Fees	45	45
Total	95	83

32 Ratio Analysis

Particulars	March 31, 2023	March 31, 2022	% Variation	Reason for variation
Current Ratio	3.08	3.76	-18.1%	Refer Note 5
Debt Equity Ratio	(3.24)	(5.99)	-45.9%	Refer note 3
Debt Service Coverage Ratio	NA	NA	NA	Refer note 4
Return on Equity Ratio	-82.20%	-51.77%	58.8%	Refer note 1
Inventory Turnover Ratio	421.76	NA	NA	Refer note 2
Trade Receivable Turnover Ratio	2.94	NA	NA	Refer note 2
Trade Payable Turnover Ratio	0.36	NA	NA	Refer note 2
Net Capital Turnover Ratio	0.19	NA	NA	Refer note 2
Net Profit Ratio	(15.75)	NA	NA	Refer note 2
Return on Capital Employed	-15.07%	-6.79%	121.9%	Refer note 1
Return on Investment	NA	NA	NA	Refer note 4

Reason for variation

1. The Profit after tax figure is decrease considerably in FY 2022-23. This has eroded the return on equity ratio.
2. Inventory / Trade Receivable / Trade payable / Net Profit Ratio are relevant for FY 2022-23 as production and Sales has commenced in the financial year.
3. The equity fund has reduced in FY 2022-23 as compared to FY 2021-22. Moreover the borrowing has increased considerably this has resulted in change in debt equity ratio.
4. This ratios is not applicable/measurable
5. Not applicable as variation is less than 25%

Numerators and Denominators considered for the aforesaid ratios:

Ratio	Numerator	Denominator
Current Ratio	Current Assets	Current Liabilities
Debt-Equity Ratio	Total Debt	Shareholder's Equity
Debt Service Coverage Ratio	Earnings available for debt service *	Debt Service **
Return on Equity Ratio	Net Profits after taxes – Preference	Average Shareholder's Equity
Inventory turnover ratio	Sales	Average Inventory
Trade Receivables turnover ratio	Revenue from Operation	Average Accounts Receivable
Trade payables turnover ratio	Adjusted Expenses	Average Trade Payables
Net capital turnover ratio	Sales	Working Capital
Net profit ratio	Net Profit	Net Sales/Income
Return on Capital employed	Earning before interest and taxes	Capital Employed ***
Return on investment	Return from Investment (Interest, Dividend, Gain/Loss)	Investments

* Earning for Debt Service = Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other

** Debt service = Interest & Lease Payments + Principal Repayments

*** Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

33 Financial Instruments - Accounting Classifications and Fair Value Measurements

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced of liquidation sale.

The following methods and assumptions were used to estimate the fair values:

Fair value of cash and cash equivalent, bank balances other than cash and cash equivalent, trade receivables, trade payables, other current financial liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities

Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.

Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

A	As at March 31, 2023	Amortised Cost	Carrying value		Total	Fair value		
			FVTPL	FVTOCI		Level 1	Level 2	Level 3
Non Current Financial assets								
	Other financial asset	1,697	-	-	1,697	-	-	-
		1,697	-	-	1,697	-	-	-
Current Financial assets								
	Trade Receivable	56	-	-	56	-	-	-
	Cash and cash equivalents	1,625	-	-	1,625	-	-	-
	Other financial assets	40	-	-	40	-	-	-
		1,721	-	-	1,721	-	-	-
	Total	3,417	-	-	3,417	-	-	-
Non - Current Financial liabilities:								
	Borrowings	3,04,978	-	-	3,04,978	-	-	-
	Lease Liabilities	8,108	-	-	8,108	-	-	-
		3,13,087	-	-	3,13,087	-	-	-
Current Financial liabilities:								
	Trade payables	2,019	-	-	2,019	-	-	-
	Other Financial Liabilities	2,497	-	-	2,497	-	-	-
	Lease Liabilities	1,193	-	-	1,193	-	-	-
		5,709	-	-	5,709	-	-	-
	Total	3,18,795	-	-	3,18,795	-	-	-
	As at March 31, 2022	Amortised Cost	Carrying value		Total	Fair value		
			FVTPL	FVTOCI		Level 1	Level 2	Level 3
Non Current Financial assets								
	Other financial asset	1,514	-	-	1,514	-	-	-
		1,514	-	-	1,514	-	-	-
Current Financial assets								
	Cash and cash equivalents	863	-	-	863	-	-	-
	Other financial assets	47	-	-	47	-	-	-
		910	-	-	910	-	-	-
	Total	2,424	-	-	2,424	-	-	-
Non - Current Financial liabilities:								
	Borrowings	2,35,462	-	-	2,35,462	-	-	-
	Lease Liabilities	9,301	-	-	9,301	-	-	-
		2,44,763	-	-	2,44,763	-	-	-
Current Financial liabilities:								
	Trade payables	2,205	-	-	2,205	-	-	-
	Other Financial Liabilities	1,545	-	-	1,545	-	-	-
	Lease Liabilities	965	-	-	965	-	-	-
		4,715	-	-	4,715	-	-	-
	Total	2,49,478	-	-	2,49,478	-	-	-

During the reporting period ended 31st March 2023 & 31st March 2022, There was no transfer between level 2 and level 3 fair value measurement.



Avery Pharmaceuticals Private Limited

Notes to the financial statements for the year ended 31st March 2023

(All amounts in Indian Rupees in thousand unless otherwise stated)

34 Additional regulatory information required by Schedule III to the Companies Act, 2013

- (i) The Company does not have any benami property held in its name. No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- (ii) The Company has not traded or invested in Crypto currency or Virtual Currency during the year.
- (iii) The Company has not come across any transaction occurred with struck-off companies under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956.
- (iv) The Company has not been declared wilful defaulter by any bank or financial institution or other lender or government or any government authority.
- (v) The Company does not have any charges or satisfaction of charges which is yet to be registered with the Registrar of the Companies beyond the statutory period.
- (vi) Utilization of borrowed funds and share premium :
- (I) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
- (b) Provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries
- (II) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) Provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries
- (vii) There is no income surrendered or disclosed as income during the year in tax assessments under the Income Tax Act, 1961 (such as search or survey), that has not been recorded in the books of account.

35 The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment had released draft rules for the Code on Social Security, 2020 on November 13, 2020, and invited suggestions from stakeholders which are under consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified. The Company will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published

36 Comparative previous year's figures have been reworked, regrouped and reclassified to the extent possible, wherever necessary to confirm to current year's classification and presentation

As per our Report fo even date.



Membership No. 040087
Place: Mumbai
Date : 27th May 2023



For and on behalf of the Board of Directors of
Avery Pharmaceuticals Private Limited


Shilpan Patel
Director
DIN No. 00341068


Neil Patel
Director
DIN No. 00607101

UDIN: 23040087BGTMXP6391